EP0666923A4 - Gezielte bereitstellung von poly- oder oligonukleotiden in zellen. - Google Patents

Gezielte bereitstellung von poly- oder oligonukleotiden in zellen.

Info

Publication number
EP0666923A4
EP0666923A4 EP19920920863 EP92920863A EP0666923A4 EP 0666923 A4 EP0666923 A4 EP 0666923A4 EP 19920920863 EP19920920863 EP 19920920863 EP 92920863 A EP92920863 A EP 92920863A EP 0666923 A4 EP0666923 A4 EP 0666923A4
Authority
EP
European Patent Office
Prior art keywords
oligonucleotides
poly
cells
targeted delivery
targeted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP19920920863
Other languages
English (en)
French (fr)
Other versions
EP0666923A1 (de
Inventor
George Y Wu
Catherine H Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Connecticut
Original Assignee
University of Connecticut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Connecticut filed Critical University of Connecticut
Publication of EP0666923A4 publication Critical patent/EP0666923A4/de
Publication of EP0666923A1 publication Critical patent/EP0666923A1/de
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP92920863A 1991-09-05 1992-09-04 Gezielte bereitstellung von poly- oder oligonukleotiden in zellen Ceased EP0666923A1 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US75508391A 1991-09-05 1991-09-05
US755083 1991-09-05
US78811991A 1991-11-04 1991-11-04
US788119 1991-11-04
US86400392A 1992-04-03 1992-04-03
US864003 1992-04-03
PCT/US1992/007339 WO1993004701A1 (en) 1991-09-05 1992-09-04 Targeted delivery of poly- or oligonucleotides to cells

Publications (2)

Publication Number Publication Date
EP0666923A4 true EP0666923A4 (de) 1995-01-20
EP0666923A1 EP0666923A1 (de) 1995-08-16

Family

ID=27419474

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92920863A Ceased EP0666923A1 (de) 1991-09-05 1992-09-04 Gezielte bereitstellung von poly- oder oligonukleotiden in zellen

Country Status (6)

Country Link
EP (1) EP0666923A1 (de)
JP (1) JPH07500820A (de)
KR (1) KR100252547B1 (de)
AU (1) AU681997B2 (de)
CA (1) CA2116107A1 (de)
WO (1) WO1993004701A1 (de)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5889169A (en) * 1991-05-16 1999-03-30 Cold Spring Harbor Laboratory Cell cycle regulatory protein p16 gene
US7550561B1 (en) 1991-05-16 2009-06-23 Cold Spring Harbor Laboratory p16INK4 polypeptides
US5981273A (en) * 1991-09-30 1999-11-09 Boehringer Ingelheim Int'l. Gmbh Composition comprising an endosomolytic agent for introducing nucleic acid complexes into higher eucaryotic cells
US5521291A (en) * 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US6627615B1 (en) 1991-12-17 2003-09-30 The Regents Of The University Of California Methods and compositions for in vivo gene therapy
US5756353A (en) * 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
US5922859A (en) * 1992-02-01 1999-07-13 Boehringer Ingelheim International Gmbh Complexes containing nucleic acid which can be taken-up by endocytosis into higher eukaryotic cells
IL105914A0 (en) * 1992-06-04 1993-10-20 Univ California Methods and compositions for in vivo gene therapy
US6806084B1 (en) 1992-06-04 2004-10-19 The Regents Of The University Of California Methods for compositions for in vivo gene delivery
US5962316A (en) 1992-10-16 1999-10-05 Cold Spring Harbor Laboratory Cell-cycle regulatory proteins, and uses related thereto
US6211334B1 (en) 1992-10-16 2001-04-03 Cold Spring Harbor Cell-cycle regulatory proteins, and uses related thereto
WO1994011494A1 (en) * 1992-11-09 1994-05-26 Thomas Jefferson University Antisense oligonucleotides to inhibit expression of mutated and wild type genes for collagen
US5574142A (en) * 1992-12-15 1996-11-12 Microprobe Corporation Peptide linkers for improved oligonucleotide delivery
US6331390B1 (en) 1992-12-17 2001-12-18 Cold Spring Harbor Laboratory Cell-cycle regulatory proteins, and uses related thereto
US6043030A (en) * 1992-12-17 2000-03-28 Cold Spring Harbor Laboratory Cell-cycle regulatory proteins, and uses related thereto
EP0681482B1 (de) * 1993-01-22 2005-12-07 University Research Corporation Lokalisierung von therapeutischen mitteln
CA2159916A1 (en) * 1993-04-05 1994-10-13 Henry C. Chiou Targeted delivery of genes encoding antisense polyribonucleotides
WO1994023751A1 (de) * 1993-04-14 1994-10-27 Boehringer Mannheim Gmbh Nukleinsäure-transferpeptide und deren verwendung zur einschleusung von nukleinsäuren in eukaryontische zellen
GB9317380D0 (en) * 1993-08-20 1993-10-06 Therexsys Ltd Transfection process
DE4331011A1 (de) * 1993-09-13 1995-03-16 Bayer Ag Nukleinsäuren-bindende Oligomere mit C-Verzweigung für Therapie und Diagnostik
DE4331012A1 (de) * 1993-09-13 1995-03-16 Bayer Ag Nukleinsäuren-bindende Oligomere mit N-Verzweigung für Therapie und Diagnostik
US7691632B2 (en) 1993-11-18 2010-04-06 Cold Spring Harbor Laboratory Kit for detecting the level of cyclin-dependent kinase inhibitor P16 gene expression
US5728518A (en) * 1994-01-12 1998-03-17 The Immune Response Corporation Antiviral poly-and oligonucleotides
JPH10501681A (ja) 1994-02-22 1998-02-17 ダナ−ファーバー キャンサー インスティチュート 核酸送達システムならびにその合成および使用方法
ATE200105T1 (de) * 1994-05-13 2001-04-15 Chiron Corp Verfahren und zusammensetzungen als vehikel zur zielgerichtete einbringen von genen
FR2721612B1 (fr) * 1994-06-23 1996-08-09 Idm Nouveaux dérivés d'oligosides, leur procédé de préparation et leurs applications.
US5728399A (en) * 1994-06-29 1998-03-17 University Of Conn. Use of a bacterial component to enhance targeted delivery of polynucleotides to cells
DE4427980A1 (de) * 1994-08-08 1996-02-15 Bayer Ag Nukleinsäuren-bindende Oligomere für Therapie und Diagnostik
AU4690596A (en) * 1994-12-30 1996-07-24 Chiron Viagene, Inc. Nucleic acid condensing agents with reduced immunogenicity
AU5259796A (en) 1995-02-10 1996-08-27 Worcester Foundation For Biomedical Research, Inc. Delivery of exogenous compounds
AU5122796A (en) * 1995-03-31 1996-10-16 Drug Delivery System Institute, Ltd. Amidite derivatives and oligonucleotide derivatives
US5856459A (en) * 1995-06-06 1999-01-05 Hybridon, Inc. Oligonucleotides specific for hepatitis B virus
CA2280997C (en) 1997-03-11 2013-05-28 Perry B. Hackett Dna-based transposon system for the introduction of nucleic acid into dna of a cell
US6524613B1 (en) 1997-04-30 2003-02-25 Regents Of The University Of Minnesota Hepatocellular chimeraplasty
EP0975370B9 (de) 1997-05-21 2004-11-03 The Board Of Trustees Of The Leland Stanford Junior University Zusammensetzung und verfahren zur verzögerung des transports durch biologische membranen
WO1998055611A1 (en) * 1997-06-06 1998-12-10 Regents Of The University Of Michigan Neuregulin response element and uses therefor
US6635623B1 (en) * 1997-06-13 2003-10-21 Baylor College Of Medicine Lipoproteins as nucleic acid vectors
AU9678598A (en) 1997-10-01 1999-04-23 Dana-Farber Cancer Institute Stabilization of envelope glycoprotein trimers by disulfide bonds introduced into a gp41 glycoprotein ectodomain
EP1053355B1 (de) 1998-02-11 2001-11-14 PE Corporation (NY) Konjugate von dns und pns und verfahren zu deren herstellung
US6210892B1 (en) * 1998-10-07 2001-04-03 Isis Pharmaceuticals, Inc. Alteration of cellular behavior by antisense modulation of mRNA processing
US7160682B2 (en) 1998-11-13 2007-01-09 Regents Of The University Of Minnesota Nucleic acid transfer vector for the introduction of nucleic acid into the DNA of a cell
DE19858005B4 (de) * 1998-12-16 2007-02-08 november Aktiengesellschaft, Gesellschaft für Molekulare Medizin Synthetisches Nucleinsäure-Partikel
US6593292B1 (en) 1999-08-24 2003-07-15 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US7229961B2 (en) 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US6271360B1 (en) 1999-08-27 2001-08-07 Valigen (Us), Inc. Single-stranded oligodeoxynucleotide mutational vectors
DE69943068D1 (de) * 1999-09-09 2011-02-03 Curevac Gmbh Transfer von mRNA unter Verwendung von polykationischen Verbindungen
AU4036600A (en) * 2000-03-28 2001-10-08 Isis Pharmaceuticals Inc Alteration of cellular behavior by antisense modulation of mrna processing
EP1286699A2 (de) * 2000-05-19 2003-03-05 Regents Of The University Of Minnesota Zusammenzsetzungen fur arzneimittelabgabe zur zellen
US7541512B2 (en) 2001-03-30 2009-06-02 Synageva Biopharma Corp. Avians containing a lysozyme promoter transgene
US7176300B2 (en) 2001-03-30 2007-02-13 Avigenics, Inc. Avian lysozyme promoter
EP1478751A4 (de) 2001-03-30 2005-10-19 Avigenics Inc Lysozym-promotor in vögeln
US7550650B2 (en) 2001-09-18 2009-06-23 Synageva Biopharma Corp. Production of a transgenic avian by cytoplasmic injection
US7294507B2 (en) 2001-11-30 2007-11-13 Avigenics, Inc. Ovomucoid promoters and methods of use
US6875588B2 (en) 2001-11-30 2005-04-05 Avigenics, Inc. Ovomucoid promoter and methods of use
US7335761B2 (en) 2001-11-30 2008-02-26 Avigenics, Inc. Avian gene expression controlling regions
US7135562B2 (en) 2002-03-14 2006-11-14 University Of Cincinnati Avian iFABP gene expression controlling region
WO2003089618A2 (en) 2002-04-22 2003-10-30 Regents Of The University Of Minnesota Transposon system and methods of use
CN100369930C (zh) 2002-11-26 2008-02-20 Pdl生物制药股份有限公司 调节血管生成的α5β1整合素的嵌合的和人源化的抗体
US7312320B2 (en) 2003-12-10 2007-12-25 Novimmune Sa Neutralizing antibodies and methods of use thereof
ES2616337T3 (es) 2003-12-12 2017-06-12 Government Of The United States Of America, As Repr. By The Secr. Of The Dept. Of Health And Human Services And His Successors Un epítopo de linfocito T citotóxico humano y su epítopo agonista del número no variable de secuencias de repetición en tándem de MUC-1
NL1027479C2 (nl) * 2004-10-21 2006-05-01 Synvolux Ip B V Bescherming van biologisch actieve moleculen met behulp van amphifielen.
CA2595848C (en) 2005-01-25 2014-06-17 Prolexys Pharmaceuticals, Inc. Erastin and erastin binding proteins, and uses thereof
WO2007109583A2 (en) 2006-03-17 2007-09-27 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for prevention or treatment of neoplastic disease in a mammalian subject
US8664364B2 (en) 2007-01-24 2014-03-04 Carnegie Mellon University Optical biosensors
US20110038935A1 (en) 2007-12-06 2011-02-17 Marasco Wayne A Antibodies against influenza virus and methods of use thereof
EP2398860B1 (de) 2009-02-18 2013-11-20 Carnegie Mellon University Gelöschte dendrimere farbstoffe zur fluoreszenzdetektion
CA2759848C (en) 2009-05-05 2018-12-04 Novimmune S.A. Anti-il-17f antibodies and methods of use thereof
EP2488210A4 (de) 2009-10-12 2014-04-30 Smith Holdings Llc Verfahren und zusammensetzungen zur modulation der genexpression mit in-vivo oder in-vitro verabreichten arzneistoffen auf oligonukleotidbasis
CN108404123A (zh) 2010-01-15 2018-08-17 康奈尔大学 降低细胞内蛋白质水平的方法
US20130040853A1 (en) 2010-01-21 2013-02-14 Dana-Farber Cancer Institute Inc. Context Specific Genetic Screen Platform to Aid in Gene Discovery and Target Validation
US9995679B2 (en) 2010-05-25 2018-06-12 Carnegie Mellon University Targeted probes of cellular physiology
AU2011261396B2 (en) 2010-06-02 2015-11-05 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
WO2012092299A1 (en) 2010-12-27 2012-07-05 Brown University Therapeutic and diagnostic methods involving biglycan and utrophin
JP6419064B2 (ja) 2012-03-29 2018-11-07 ノビミューン エスアー 抗ｔｌｒ４抗体およびその使用
AU2013256010B2 (en) 2012-05-04 2018-01-04 Dana-Farber Cancer Institute, Inc. Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use
BR112015007672A2 (pt) 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
AU2013353763B2 (en) 2012-12-03 2018-09-13 Novimmune S.A. Anti-CD47 antibodies and methods of use thereof
WO2015143194A2 (en) 2014-03-19 2015-09-24 Dana-Farber Cancer Institute, Inc. Immunogenetic restriction on elicitation of antibodies
EP4112070A1 (de) 2014-04-25 2023-01-04 Dana Farber Cancer Institute, Inc. Mers-coronavirus-neutralisierende antikörper und verfahren zu ihrer verwendung
TWI695011B (zh) 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 抗ｈｅｒ２表位之單株抗體及其使用之方法
WO2016054638A1 (en) 2014-10-03 2016-04-07 Dana-Farber Cancer Institute, Inc. Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof
AU2015328273B2 (en) 2014-10-06 2020-09-17 Dana-Farber Cancer Institute, Inc. Humanized CC chemokine receptor 4 (CCR4) antibodies and methods of use thereof
WO2016081440A1 (en) 2014-11-17 2016-05-26 Carnegie Mellon University Activatable two-component photosensitizers
AU2015350190B2 (en) 2014-11-18 2021-08-05 Janssen Pharmaceutica Nv CD47 antibodies, methods, and uses
JP7033082B2 (ja) 2016-02-05 2022-03-09 ナノビュー バイオサイエンシズ インコーポレイテッド 表面マーカーを有するエキソソームの検出
WO2017160754A1 (en) 2016-03-15 2017-09-21 Mersana Therapeutics,Inc. Napi2b-targeted antibody-drug conjugates and methods of use thereof
CA3031194A1 (en) 2016-07-22 2018-01-25 Dana-Farber Cancer Institute, Inc. Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof
EP3507305A1 (de) 2016-09-02 2019-07-10 Dana-Farber Cancer Institute, Inc. Zusammensetzung und verfahren zur behandlung von b-zell-erkrankungen
MX2019002696A (es) 2016-09-06 2019-09-27 Dana Farber Cancer Inst Inc Metodos para tratar o prevenir una infeccion del virus del zika.
TW201825511A (zh) 2016-09-09 2018-07-16 美商艾斯合顧問有限公司 表現免疫檢查點調節子的溶瘤病毒
AU2019235523A1 (en) 2018-03-14 2020-10-29 Novimmune Sa Anti-CD3 epsilon antibodies and methods of use thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ROTHENBERG, M. ET AL.: "Oligodeoxynucleotides as anti-sense inhibitors of gene expression: therapeutic implications", JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 81, no. 20, 18 October 1989 (1989-10-18), BETHESDA, MD, USA, pages 39 - 44, XP000351436 *
See also references of WO9304701A1 *
WU, G. & WU, C.: "DELIVERY SYSTEMS FOR GENE THERAPY.", BIOTHERAPY (DORDR) 3 (1). 1991. 87-96 *
WU, G. ET AL.: "RECEPTOR-MEDIATED IN-VITRO GENE TRANSFORMATION BY A SOLUBLE DNA CARRIER SYSTEM.", J BIOL CHEM 262 (10). 1987. 4429-4432 *

Also Published As

Publication number Publication date
CA2116107A1 (en) 1993-03-18
AU2678092A (en) 1993-04-05
AU681997B2 (en) 1997-09-18
EP0666923A1 (de) 1995-08-16
JPH07500820A (ja) 1995-01-26
KR100252547B1 (ko) 2000-09-01
WO1993004701A1 (en) 1993-03-18

Similar Documents

Publication Publication Date Title
EP0666923A4 (de) Gezielte bereitstellung von poly- oder oligonukleotiden in zellen.
NO943198D0 (no) Antisensoligonukleotidinhibering av papillomavirus
EP0654973A4 (de) Anordnung zur abgabe von medikamenten an das lymphgewebe.
GB9723081D0 (en) Dosage form comprising oxybutynin
ZA886435B (en) Dosage form comprising fast agent delivery followed by slow agent delivery
IL105824A0 (en) Single use intrauterine injector
EP0690716A4 (de) Modifizierte oligonukleotide zur verbesserung der stabilität im saurem ph-bereich
GB9224640D0 (en) Stable oligonucleotides
GB9225427D0 (en) Oligonucleotides with rna cleavage activity
EP0667778A4 (de) Behandlung von melanomen mit antisense oligonukleotiden gegen das c-myb-protoonkogen.
ITMI921235A1 (it) Oligonucleotidi antisenso ad attivita' antitumorale, composizioni farmaceutiche che li comprendono, e loro impieghi
PH31659A (en) Therapeutic nucleotides.
EP0489846A4 (en) Antisense oligonucleotides to c-abl proto-oncogene
IL99172A0 (en) Antisense oligonucleotides which are active as antiviral agents
AU1562492A (en) Substituted salicylamides, agents to combat plant diseases
DE3369680D1 (en) Benzotriazoles, their preparation and use as biocides
AU5086393A (en) Antisense oligonucleotides to cyclin d1 proto-oncogene
AU5136693A (en) Antisense oligonucleotides to b myb proto-oncogene
EP0580795A4 (en) Antisense oligonucleotides to c-kit proto-oncogene and uses thereof
ITMI941560A0 (it) Oligonucleotidi antisenso complementari all'rna messaggero del recettore umano della urochinasi
ZA928126B (en) Use of substituted tetrahydrothiophenes, some of wich are known as medicaments, new active substances and processes for their preparation.
DE69320154D1 (de) Menschliche Id-Gene
Cribb Path to glory: the social impact of the growth of mormonism.
EP0662782A4 (de) Pp14-basierte therapie.
ITMI913352A1 (it) Procedimento per trattare pile esauste.

Legal Events

Date Code Title Description
A4 Supplementary search report drawn up and despatched
AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940329

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE

17Q First examination report despatched

Effective date: 19970513

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20030306